View in EDS

Isoniazidinduceret toksisk hepatitis

Saved in:
Bibliographic Details
Title: Isoniazidinduceret toksisk hepatitis
Authors: Kristensen, Kristina Langholz, Nordholm, Anne Christine, Clausen, Mette Rye, Katzenstein, Terese L
Source: Kristensen, K L, Nordholm, A C, Clausen, M R & Katzenstein, T L 2021, ' Isoniazidinduceret toksisk hepatitis ', Ugeskrift for Laeger, bind 183, nr. 6, V10200770 . < https://content.ugeskriftet.dk/sites/default/files/scientific_article_files/2021-01/v10200770_web.pdf >
Publisher Information: 2021.
Publication Year: 2021
Subject Terms: Adult, Male, Antitubercular Agents/adverse effects, Hepatitis/drug therapy, Humans, Isoniazid/adverse effects, Latent Tuberculosis/drug therapy, 3. Good health
Description: Hepatotoxicity is a well-known side effect to isoniazid treatment with the risk of progression to liver failure. This case report describes a 39-year-old male, who received standard isoniazid treatment for latent TB infection (LTBI) and developed severe isoniazid-induced acute hepatitis. Liver transplantation was considered, but the patient slowly recovered with full hepatic regeneration. With increasing focus on treating LTBI in Denmark, routine follow-up including biochemical monitoring should be implemented for patients receiving LTBI treatment to prevent severe complications.
Document Type: Article
File Description: application/pdf
Language: Danish
Access URL: https://curis.ku.dk/ws/files/337986729/v10200770_web.pdf
Accession Number: edsair.od......2751..02728ceb7e8bb63575beff88bbc10ca5
Database: OpenAIRE
Description
Abstract:Hepatotoxicity is a well-known side effect to isoniazid treatment with the risk of progression to liver failure. This case report describes a 39-year-old male, who received standard isoniazid treatment for latent TB infection (LTBI) and developed severe isoniazid-induced acute hepatitis. Liver transplantation was considered, but the patient slowly recovered with full hepatic regeneration. With increasing focus on treating LTBI in Denmark, routine follow-up including biochemical monitoring should be implemented for patients receiving LTBI treatment to prevent severe complications.